89bio, Inc. (ETNB) has a consensus analyst rating of Buy, based on 15 analysts covering the stock. Of those, 9 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for ETNB is $22.00, representing a +48.2% upside from the current price of $14.84. Price targets range from a low of $12.00 to a high of $29.00.
